Bispecifics and multispecifics at Festival of Biologics 2026
Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website
13 organizations at Festival of Biologics 2026 present work in bispecifics & multispecifics: 7 suppliers and service providers, 4 drug developers and 2 academic, government and non-profit bodies. Between them they bring 29 presentations to the program. Most represented: Merck KGaA (6 on the program), Lonza (6 on the program), Ichnos Glenmark Innovation (4 on the program). 12 of them have their own page in this guide. As of Sep 26, 2026.
Format
Top represented
Showing 1–12 of 13 organizations
| Organization | Festival of Biologics 2026 Attendance |
|---|---|
Merck KGaA Darmstadt, Germany | |
German science and technology company in healthcare, life science (including bioprocessing products) and electronics. | Chair Tue Oct 13 16:45 Talk Tue Oct 13 17:30 Talk Wed Oct 14 11:50 Talk Wed Oct 14 14:10 Talk Wed Oct 14 14:10 |
Lonza Basel, Switzerland | |
Contract development and manufacturing partner for biologics, cell and gene therapies and small molecules. | Booth Exhibiting at Booth 450 Talk Tue Oct 13 17:10 De-risking Lyophilization Scale-Up Using predictive models How computer models of freeze-drying can predict what happens at full manufacturing scale, cutting experiments and the risk of a failed transfer. Keynote Wed Oct 14 09:55 From Experimentation to Prediction: How Data-Driven Innovation is Forging Predictability Across Biologics Development and Precision Biomanufacturing Why biologics developers still decide by trial and error, and how treating every program as shared learning could make outcomes more predictable. Bioprocessing & manufacturingAI & computational design Talk Wed Oct 14 12:30 Accelerating CHO Cell Line Development Through Next-Generation Expression System Design How improved cell engineering, promoter design and selection methods shorten the path from DNA to a cell line that makes a drug. Talk Wed Oct 14 14:30 Beyond mAbs: accelerated Gene-to-IND development for bispecifics, Fc-fusions and high-concentration biologics Faster routes from DNA to first clinical trials for complex antibody drugs, and the problems they create in making, purifying and formulating them. |
IG Ichnos Glenmark Innovation New York, NY | |
Talk Tue Oct 13 14:50 BEAT®: A Platform to Advance Developable Multispecific Therapeutic Antibodies to the Clinic A platform for building antibodies that grip several targets at once, using a shared light chain and pairing ideas borrowed from T-cell receptors. Chair Wed Oct 14 09:00 Chair Wed Oct 14 14:05 Talk Wed Oct 14 15:30 Talk Thu Oct 15 11:40 | |
Technical University of Denmark Kongens Lyngby, Denmark | |
Talk Tue Oct 13 15:30 Talk Tue Oct 13 17:30 Talk Wed Oct 14 12:10 Talk Wed Oct 14 14:50 Talk Thu Oct 15 11:20 Elimination of CHO clonal variation allows skipping clone screenings Using enzymes called recombinases to insert genes so that cell clones behave almost identically, letting developers skip clone screening entirely. | |
Cue Biopharma Boston, MA | |
Talk Wed Oct 14 11:30 | |
MacroGenics Rockville, MD | |
Develops antibody-based cancer therapeutics, including bispecifics and antibody-drug conjugates. | Chair Wed Oct 14 11:25 Chair Wed Oct 14 14:05 |
ATUM Newark, CA | |
Gene synthesis, protein engineering and Leap-In transposase cell line development tools and services for biologics developers. | Booth Exhibiting at Booth 278 Talk Wed Oct 14 11:50 Overcoming Manufacturing Bottlenecks in Multispecific Design via Native Scaffold Engineering How keeping the natural antibody shape, with few mutations, helps multi-target antibodies assemble correctly and stay easy to make. |
Family-owned CRDMO combining preclinical research and clinical manufacturing of therapeutic proteins from mammalian cells at one site. | Booth Exhibiting at Booth 224 Talk Wed Oct 14 14:50 Designing Manufacturability into Multispecifics Early: How Integrated CRDMO De-risks Biologics Programs and Accelerates Development Why checking how easy complex biologics are to make before picking a final candidate leads to faster, cheaper, lower-risk development. |
Harbour BioMed's discovery company, offering Harbour Mice antibody platforms (H2L2, HCAb) and discovery services for antibodies, multispecifics, ADCs and CAR-T binders. | Booth Exhibiting at Booth 424 Keynote Wed Oct 14 09:30 Novel Next-generation Multispecifics, CAR-Ts & ADCs from H2L2 & HCAb Harbour Mice® How mice that make human antibodies, including heavy-chain-only ones, are used to build multi-target antibodies, CAR-T cells and antibody–drug conjugates for cancer. Bispecifics & multispecificsADCs & armed antibodies |
Twist Bioscience South San Francisco, CA | |
Makes synthetic DNA and gene libraries and offers antibody discovery and multispecific development, including the B-Body platform. | Booth Exhibiting at Booth 349 Talk Tue Oct 13 13:10 Accelerating multispecific antibody discovery & development with the B-Body platform How to build antibodies that bind two or more targets without mismatched light chains and purify them like ordinary antibodies. Bispecifics & multispecifics |
University of Stuttgart Stuttgart, Germany | |
Talk Wed Oct 14 14:30 | |
AI platform for sterically guided design of bispecific and multispecific antibodies and for prioritizing wet-lab experiments. | Booth Exhibiting at Booth S21 |
Instantly find 20 buyers in bispecifics & multispecifics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse Festival of Biologics 2026 by
Organization type
Topic
- Antibody & protein engineering 67
- AI & computational design 38
- Bispecifics & multispecifics 13
- ADCs & armed antibodies 18
- Immunotherapy & oncology 44
- Cell & gene therapy 28
- Therapeutic vaccines 13
- Peptides & GLP-1 7
- Bioprocessing & manufacturing 87
- CMC, formulation & analytics 58
- Clinical development 45
- Regulation & market access 40
Exhibit hall
Everyone
Not affiliated with or endorsed by Terrapinn or the Festival of Biologics. Submit a correction